Radiopharmaceuticals / Peptide Receptor Radionuclide Therapeutics, LUTATHERAⓇ Injection, Lutetium（177Lu） oxodotreotide

Kawata Tadayuki

doi:10.2745/dds.38.165

Bibliographic Information

Other Title

放射性医薬品／ペプチド受容体放射性核種療法剤ルタテラⓇ静注　ルテチウムオキソドトレオチド（177Lu）

Abstract

Lutathera^Ⓡ injection is the first peptide receptor radionuclide therapy radiopharmaceutical in Japan for the treatment of somatostatin receptor（SSTR） positive neuroendocrine tumor（NET）. After somatostatin analogue labeled with radioactive Lutetium 177（¹⁷⁷Lu） is administered, it binds to somatostatin receptors, is taken up into tumor cells, and beta rays released from ¹⁷⁷Lu induce DNA damage and exert a cell growth-inhibitory effect. International Phase III study NETTER -1 demonstrated the efficacy and safety of this product in patients with SSTR-positive, unresectable or metastatic midgut NET. Lutathera^Ⓡ was approved in 31 European countries in September 2017, followed by the US, Canada, South Korea, Taiwan, and other countries. In Japan, efficacy and safety were confirmed in a Japanese phase I/II study in patients with SSTR positive unresectable or metastatic pancreatic, gastrointestinal, or pulmonary NET, and approval was obtained in June 2021.

Journal

Drug Delivery System

Drug Delivery System 38 (2), 165-170, 2023-03-25

THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Keywords

Details 詳細情報について

CRID: 1390578050263036672

DOI: 10.2745/dds.38.165

ISSN: 18812732; 09135006

Web Site: https://www.jstage.jst.go.jp/article/dds/38/2/38_165/_pdf

Text Lang: ja

Data Source

JaLC
Crossref

Abstract License Flag: Disallowed

Export

Radiopharmaceuticals / Peptide Receptor Radionuclide Therapeutics, LUTATHERA<sup>Ⓡ</sup> Injection, Lutetium（<sup>177</sup>Lu） oxodotreotide